

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CLARITY MEDICAL GROUP HOLDING LIMITED

### 清晰醫療集團控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1406)**

### ADDITIONAL RESUMPTION GUIDANCE AND CONTINUED SUSPENSION OF TRADING

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of Clarity Medical Group Holding Limited (the “**Company**”, which together with its subsidiaries are collectively referred to the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Future Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the announcement of the Company dated 30 May 2025 (the “**Announcement**”) on the resumption guidance (the “**First Resumption Guidance**”) for the Company issued by the Stock Exchange on 20 May 2025. Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

#### ADDITIONAL RESUMPTION GUIDANCE

On 26 June 2025, the Company received a letter from the Stock Exchange setting out the following additional resumption guidance (the “**Additional Resumption Guidance**”, together with the First Resumption Guidance, the “**Resumption Guidance**”) for the resumption of trading in the shares of the Company on the Stock Exchange:

- (a) publish all outstanding financial results required under the Listing Rules and address any audit modifications; and
- (b) demonstrate the Company’s compliance with Rule 13.24 of the Listing Rules.

#### FULL RESUMPTION GUIDANCE TO DATE

Following the inclusion of the Additional Resumption Guidance, the full Resumption Guidance to date is as follows:

- (i) conduct an independent forensic investigation into the Allegations and related matters (including but not limited to any other allegations and/or accusations received by the Board from time to time which are connected to or arise from the Allegations), assess the impact on the Company's business operations and financial position, announce the findings and take appropriate remedial actions;
- (ii) demonstrate that there is no reasonable regulatory concern about the integrity, competence and/or character of the Group's management and/or any person with substantial influence over the Company's management and operations, which may pose a risk to investors and damage market confidence;
- (iii) conduct an independent internal control review and demonstrate that the Company has in place adequate internal control and procedures to comply with the Listing Rules;
- (iv) re-comply with Rules 3.10(1), 3.10(2), 3.10A, 3.21, 3.25 and 3.27A of the Listing Rules;
- (v) inform the market of all material information for the Company's shareholders and investors to appraise the Company's position;
- (vi) publish all outstanding financial results required under the Listing Rules and address any audit modifications; and
- (vii) demonstrate the Company's compliance with Rule 13.24 of the Listing Rules.

Further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the Listing Rules to update its shareholders and potential investors on the progress in complying with the Resumption Guidance.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Tuesday, 15 April 2025 and will remain suspended until further notice.

**Shareholders and potential investors of the Company should exercise caution when dealing in the shares or other securities of the Company, and if they are in any doubt about their position, they should consult their independent professional adviser(s).**

By Order of the Board  
**CLARITY MEDICAL GROUP HOLDING LIMITED**  
**WU Ting Yuk Anthony**  
*Non-Executive Director and Chairman*

Hong Kong, 30 June 2025

*As at the date of this announcement, the Board comprises Mr. JIANG Bo, Mr. HUI Yung Chris, Dr. TSE Wai Ip and Mr. LO Tsz Hong as executive Directors, Mr. WU Ting Yuk Anthony as Chairman and non-executive Director and Ms. CHENG Jessica, Mr. WANG Can and Ms. CI Ying as independent non-executive Directors.*